


Cite this: *RSC Adv.*, 2024, 14, 37950

Synthesis of a multivalent α -1,2-mannobiose ligand for targeting C-type lectins†

Jannis Langer, ^{ab} Laura Hartmann ^{*ab} and Nicole L. Snyder ^{*c}

The importance of lectins in biological processes such as pathogen recognition, cell adhesion, and cell recognition is well documented. C-Type lectins, which require calcium for binding, play an important role in the innate immune response by engaging carbohydrates presented as part of the human and pathogen glycocalyx. For example, lectins such as MBL, Dectin-2, langerin and DC-SIGN selectively recognize mannose rich (high-mannose) structures presented as part of the glycocalyx. One common sugar binding motif that is recognized by these lectins on the pathogen glycocalyx is α -1,2-mannobiose, a disaccharide that consists of two mannose units connected via a α -1,2-linkage. To study the binding of these motifs in different contexts, synthetic replicas of α -1,2-mannobiose that can be presented in a multivalent fashion mimicking their presentation on the glycocalyx are required. Here we present the synthesis of a novel α -1,2-mannobiose analog bearing an azido linker from known precursors using a split and combine approach guided by neighboring group participation. Our approach makes it possible to achieve comparatively high yields and stereoselectivities while reducing the number of steps required to prepare such structures. We also introduce, for the first time, the trivalent presentation of our α -1,2-mannobiose ligand on a precision glycomacromolecule using copper-catalyzed azide–alkyne cycloaddition (CuAAC) to create high-mannose mimetics. Such structures have the potential to serve as probes for unlocking the rules of engagement between high-mannose glycans and C-type lectins like langerin and DC-SIGN.

Received 10th September 2024
Accepted 20th November 2024

DOI: 10.1039/d4ra06526c

rsc.li/rsc-advances

1 Introduction

α -1,2-Mannobiose, where the two mannose saccharides are connected via an α -1,2-glycosidic linkage (Man α (1–2)Man α), is a common motif found in the terminal regions of glycosylated chains on the pathogens glycocalyx¹ where it serves as an important recognition element for several C-type lectins involved in innate immunity such as Dectin-2, MBL (mannose binding lectin), langerin and DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin).^{2–7} For this reason, there is significant interest in understanding how the presentation of α -1,2-mannobiose influences its engagement with these lectins and, in turn, the corresponding immune response. This has led to the desire for increased access to synthetic α -1,2-mannobiose ligands that can be used for such studies. Notably, such structures are neither readily nor commercially available.

The few examples in literature that build up a selective α -1,2-linkage between two mannose units often include the use of highly toxic chemicals such as mercury(II) bromide and/or involve complex synthetic approaches.^{8–10} In addition, most synthetic routes lack modularity limiting further application *e.g.* for multivalent presentation or further chemical modification.^{10,11} In an effort to overcome these limitation we sought to develop a more convenient method based on the split and combine approach by Gronenborn *et al.*¹² that would provide us with both a linker for multivalent presentation and options for further structural exploration including extensions of the glycan chain.

Our efforts in this area are aligned with our goals to develop precision glycomacromolecules as glycomimetics.^{13–16} Our approach, which is based on known precursors, provides for a modular synthetic route to a novel α -1,2-mannobiose ligand with an anomeric azidoethanol linker for multivalent presentation via click chemistry, and a temporary 2'-O-protecting group for possible further extension via glycosylation. Furthermore, as proof of principle, we demonstrate, for the first time, the utility of this structure through its subsequent conjugation to a sequence defined oligo(amido)amine scaffold. The resulting glyco-oligo(amidoamine), which serves as a high-mannose glycan mimetic, will be used in the future as a tool to explore how the presentation of α -1,2-mannobiose influences C-type lectin binding and immune function.

^aInstitute for Organic Chemistry and Macromolecular Chemistry, Heinrich Heine University Düsseldorf, Universitätsstraße 1, Düsseldorf 40225, Germany

^bInstitute for Macromolecular Chemistry, University Freiburg, Stefan-Meier-Str. 31, 79104 Freiburg i.Br., Germany. E-mail: laura.hartmann@makro.uni-freiburg.de

^cDepartment of Chemistry, Davidson College, Davidson, NC 28035, USA. E-mail: nlsnyder@davidson.edu

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra06526c>



2 Material and methods

2.1 Chemicals

All chemicals used were purchased from commercial suppliers and used without further purification. D(+)-Mannose (99%) was purchased from Abcr GmbH. Acetonitrile (Reag. Ph. Eur., for UHPLC) and triethylamine (ultrapure) were purchased from AppliChem. *p*-Toluenesulfonic acid (98%), acetic acid (99.8%), 2,4,6-collidine (99%), methanol ($\geq 99.8\%$), sodium hydride (60% dispersion in mineral oil), tin(II) triflate (97%), Celite 535 coarse, sodium ascorbate (99.0%), TIPS (98%) and diethyl ether ($\geq 99.8\%$) were purchased from Sigma-Aldrich. Acetic anhydride (99%) was purchased from Grüssing GmbH. Ethyl acetate (analytical reagent grade), sodium hydrogen carbonate (analytical reagent grade), dichloromethane (99.99%), and toluene (analytical reagent grade) were purchased from Fischer Scientific. Hydrogen bromide 33% (w/w) in acetic acid was purchased from Thermo Scientific. Magnesium sulphate was acquired from VWR BDH Prolabo Chemicals. *n*-Hexane (97%) was purchased from HiPerSolv CHROMANORM. Ethanol (99%) was purchased from ChemSolute. Sodium methoxide (98%) and boron trifluoride diethyl etherate were purchased from Alfa Aesar. DMF (99.8%, for peptide synthesis), benzyl bromide, ethanethiol (99+ %), sodium azide, piperidine (99%), and copper(II) sulphate (98%) were purchased from Acros Organics. *N*-Iodosuccinimide (98%) was purchased from BLDPharm. *N,N*-Diisopropylethylamine ($\geq 99\%$) was purchased from Carl Roth. PyBOP and trifluoroacetic acid (99%) were purchased from Fluorochem. Tentagel S RAM resin (loading: 0.23 mmol g⁻¹) was purchased from RAPP Polymers.

2.2 Analytical methods

¹H-NMR measurements were recorded using a Bruker Avance III 600 (600 MHz) at room temperature. ¹³C-NMR measurements were recorded using a Bruker Avance Neo 400 (100 MHz) at room temperature. All ¹H spectra are referenced to their solvent peaks (CDCl₃: δ = 7.26 ppm, DMSO-*d*₆: δ = 2.50 ppm, D₂O: δ = 4.79 ppm, MeOH-*d*₄: δ = 4.87 ppm). The multiplicities are given as follows s = singlet, d = doublet, t = triplet, q = quartet and m = multiplet. The coupling constant *J* was given in Hz. All ¹³C spectra are referenced to their solvent peaks (CDCl₃: δ = 77.16 \pm 0.06 ppm).

MALDI-TOF MS measurements were recorded on the Ultraflex I instrument from Bruker Daltonics. 2,5-Dihydroxybenzoic acid (DHB) and α -cyano-4-hydroxycinnamic acid (CHCA) were used as matrices. The ratio of the compound to be analysed to the matrix was 10 : 1.

The HRMS spectra were recorded on the UHR QTOF maXis 4G instrument from Bruker Daltonics.

RP-HPLC MS measurements were performed on an Agilent 1260 Infinity instrument coupled to a wavelength detector (VWD, set to 214 nm) and a 6120 quadrupole LC/MS electron spray ionisation (ESI) source (positive mode, *m/z* = 200 to 2000). The column used was an MZ-AquaPerfekt C18 (3.0 \times 50 mm, 3 μ m) RP (reverse phase) column from Mz-Analysentechnik with a flow rate of 0.4 mL min⁻¹ at 25 °C. A water/acetonitrile mixture

mixed with 0.1 vol% formic acid was used as eluent. All purities were determined by integration of the RP-HPLC spectrum.

The ESI MS measurements were performed on the aforementioned instrument.

The FTIR measurements were recorded on a Fourier-Transform IR spectrometer FTIR 55XB from Nicolet.

Lyophilisation was performed with an Alpha 1-4 LD plus instrument from Martin Christ Freeze Dryers GmbH. The parameters chosen during the process were -52 °C and 0.1 mbar.

The thin-layer chromatography was carried out on TLC plates from E. Merck Silica Gel 60 F252 (0.25 mm thickness) and the spots were stained using an anisaldehyde/sulphuric acid solution and subsequent heating of the DC plates.

Flash chromatography was carried out using the CombiFlash R_f device from Teledyne ISCO.

2.3 α -1,2-Mannobioseazide synthesis

2.3.1 Penta-*O*-acetyl-*D*-mannose (2). Commercially available (*D*)-mannose (35 g, 194.27 mmol) was dissolved in 500 mL acetonitrile at 0 °C followed by a catalytic amount of *p*-toluenesulfonic acid (4 g). The mixture was allowed to stir for 1 h. Then, acetic anhydride (126.93 g, 117.53 mL, 1243.33 mmol) was slowly added at 0 °C over about 30 min. After the addition, the ice bath was removed, and the solution was left to stir for approx. 24 h. The solution, now a slightly yellow, was checked for complete conversion by TLC (1 : 1 ethyl acetate : *n*-hexane, v/v, R_f = 0.6). Upon completion, the solvent was removed by rotary evaporation. The remaining oil was dissolved in 250 mL ethyl acetate and washed three times each with 250 mL sodium hydrogen carbonate solution and 300 mL water. The collected organic phases were dried over magnesium sulphate and the solvent was removed on the rotary evaporator under reduced pressure to provide the desired product **2** in 98% yield. ¹H-NMR: (600 MHz, chloroform-*d*) δ (ppm) 6.07 (d, ³*J*_{H1 α -H2 α} = 1.89 Hz, 1H, H1 α), 5.85 (d, ³*J*_{H1 β -H2 β} = 1.20 Hz, 0.5H, H1 β), 5.47 (dd, ³*J*_{H2 β -H1 β} = 1.19 Hz, ³*J*_{H2 β -H3 β} = 3.32, 0.5H, H-2 β), 5.34–5.32 (m, 2H, H2 α , H3 α), 5.30–5.24 (m, 1.5H, H3 β , H3 α), 5.12 (dd, ³*J*_{H4 β -H3 β} = 3.30 Hz, ³*J*_{H4 β -H5 β} = 9.97 Hz, 0.5H, H4 β), 4.31–4.25 (m, H6 α , H6 β , 1.5H), 4.15–4.05 (m, 1.5H, H6' α , H6' β), 4.07–4.00 (m, 1H, H5 α) 3.81–3.77 (m, 0.5H, H5 β), 2.20 (s, 1.5H, β -C(O)CH₃), 2.16 (s, 3H, α -C(O)CH₃), 2.15 (s, 3H, α -C(O)CH₃), 2.09 (s, 1.5H, β -C(O)CH₃), 2.08 (s, 3H, α -C(O)CH₃), 2.04 (s, 3H, α -C(O)CH₃), 2.03 (s, 1.5H, β -C(O)CH₃), 1.99 (s, 3H, α -C(O)CH₃), 1.98 (s, 1.5H, β -C(O)CH₃). HRMS calculated for C₁₆H₂₂NaO₁₁ [M + Na]⁺ 413.1054; found 413.1057, calculated for the fragmentation product C₁₄H₁₉O₉ [M + H]⁺ 331.1024 found 331.1018. RP HPLC: (linear gradient from 0 to 50 vol% MeCN in H₂O in 30 min at 25 °C) *t*_R = 20.86 min and *t*_R = 21.87 min, respectively.

2.3.2 1-Bromo-2,3,4,6-tetra-*O*-acetyl-*D*-mannopyranoside (3). This compound was synthesized as described by Ahadi *et al.*⁹ Penta-*O*-acetyl-*D*-mannose (**2**) (76.84 g, 197.11 mmol) was dissolved in 70 mL acetic acid and 6 mL acetic anhydride at 40 °C and placed under a nitrogen atmosphere. The solution was then cooled to 0 °C and cold hydrobromic acid was added slowly. After approx. 30 min, the ice bath was removed, and the

solution was left to stir overnight. After checking for complete conversion by TLC (2 : 1 *n*-hexane : ethyl acetate v/v, $R_f = 0.5$), 400 mL chloroform was added to the solution, and the organic phase was washed three times each with sodium hydrogen carbonate solution and water (100 mL per washing). Subsequently, the organic phase was dried over magnesium sulphate and concentrated on the rotary evaporator to provide the desired product **3** in 97% yield. $^1\text{H-NMR}$: (600 MHz, chloroform- d) δ (ppm) 6.28 (d, $^3J_{\text{H1-H2}} = 0.95$ Hz, 1H, H1), 5.70 (dd, $^3J_{\text{H4-H5}} = 10.17$ Hz, $^3J_{\text{H4-H3}} = 3.42$ Hz, 1H, H4), 5.43 (dd, $^3J_{\text{H2-H1}} = 1.64$ Hz, $^3J_{\text{H2-H3}} = 3.45$ Hz, 1H, H2), 5.35 (t, $^3J_{\text{H3-H4}} = 10.18$ Hz, 1H, H3), 4.31 (dd, $^2J_{\text{H6-H6'}} = 12.55$ Hz, $^3J_{\text{H6-H5}} = 4.93$ Hz, 1H, H6), 4.20 (m, 1H, H5), 4.12 (dd, $^2J_{\text{H6'-H6}} = 12.53$ Hz, $^3J_{\text{H6'-H5}} = 2.23$ Hz, 1H, H6'), 2.16 (s, 3H, $-\text{C}(\text{O})\text{CH}_3$), 2.09 (s, 3H, $-\text{C}(\text{O})\text{CH}_3$), 2.06 (s, 3H, $-\text{C}(\text{O})\text{CH}_3$), 1.99 (s, 3H, $-\text{C}(\text{O})\text{CH}_3$). HRMS: calculated for the fragmentation product $\text{C}_{14}\text{H}_{19}\text{O}_9$ $[\text{M} + \text{H}]^+$ 331.1024 found 331.1018. RP HPLC: (linear gradient from 0 to 50 vol% MeCN in H_2O in 30 min at 25 °C) $t_R = 10.34$ min.

2.3.3 1,2-*O*-(1-Methoxyethylidene)-3,4,6-tri-*O*-acetyl- D -mannopyranoside (4**).** This compound was synthesized as described by Ahadi *et al.*⁹ 1-Bromo-2,3,4,6-tetra-*O*-acetyl- D -mannopyranoside (**3**) (78.02 g, 206.76 mmol) was dissolved in 30 mL acetonitrile and 2,4,6-collidine (1.54 eq., 318.41 mmol, 42.22 mL) at room temperature. To the solution was added 33.54 mL methanol and the resulting mixture was allowed to stir in the dark overnight. The progress of the reaction was monitored by TLC (3 : 1 *n*-hexane : ethyl acetate, v/v, $R_f = 0.6$). Upon completion, the solution was diluted with 350 mL chloroform and washed three times with water (300 mL of water per washing). The aqueous phase was also extracted once with 200 mL chloroform. The combined organic phases were dried over magnesium sulphate and concentrated by rotary evaporation. The residue was recrystallized from an ethanol/*n*-hexane mixture, precipitating a white solid to provide the desired product **4** in 57% yield. $^1\text{H-NMR}$: (600 MHz, chloroform- d) (ppm) δ 5.48 (d, $^3J_{\text{H1-H2}} = 1.01$ Hz, 1H, H1exo), 5.38 (t, $^3J_{\text{H2-H3}} = 9.99$ Hz, 0.33H, H2endo), 5.28 (t, $^3J_{\text{H2-H3}} = 9.79$ Hz, 1H, H2exo), 5.25 (d, $^3J_{\text{H1-H2}} = 1.08$ Hz, 0.33H, H1endo), 5.19 (dd, $^2J_{\text{H6-H6'}} = 10.07$ Hz, $^3J_{\text{H6-H5}} = 4.15$ Hz, 0.33H, H6endo), 5.13 (dd, $^2J_{\text{H6-H6'}} = 9.98$ Hz, $^3J_{\text{H6-H5}} = 4.03$ Hz, 1H, H6exo), 4.62–4.57 (m, 1H, H6'exo), 4.39–4.35 (m, 0.33H, H6'endo), 4.28–4.19 (m, 1.33H, H5endo + exo), 4.16–4.08 (m, 1.33H, H4endo + exo), 3.74–3.64 (m, 1.33H, H3endo + exo), 3.48 (s, 1H, $-\text{O}-\text{CH}_3$ (endo)), 3.27 (s, 3H, $-\text{O}-\text{CH}_3$ (exo)), 2.11 (s, 4H, $-\text{C}(\text{O})\text{CH}_3$ (endo + exo)), 2.06 (s, 3H, $-\text{C}(\text{O})\text{CH}_3$ (exo)), 2.04 (s, 4H, $-\text{C}(\text{O})\text{CH}_3$ (endo + exo)), 2.01 (s, 1H, $-\text{C}(\text{O})\text{CH}_3$ (endo)), 1.73 (s, 3H, $-\text{CH}_3$ (exo)), 1.51 (s, 1H, CH_3 (endo)). HR-MS: calculated for $\text{C}_{15}\text{H}_{22}\text{NaO}_{10}$ $[\text{M} + \text{Na}]^+$ 385.1105; found 385.1106.

2.3.4 1,2-*O*-(1-Methoxyethylidene)- D -mannopyranoside (5**).** This compound was synthesized as described by Ahadi *et al.*⁹ 1,2-*O*-(1-methoxyethylidene)-3,4,6-tri-*O*-acetyl- D -mannopyranoside (**4**) (23.41 g, 64.61 mmol) was dissolved in 14.85 mL dichloromethane and 148.53 mL methanol at room temperature. To the solution was added 10 mL of a 1 M sodium methoxide solution in methanol, producing a slight turbid mixture. The solution was allowed to stir for 2 h and checked by TLC (3 : 1, *n*-hexane : ethyl acetate v/v, $R_f = 0.8$). Upon completion, the solvent was removed under reduced pressure and the product

was used without further purification. $^1\text{H-NMR}$ (600 MHz, methanol- d_4) δ (ppm) 5.46 (d, $^3J_{\text{H1-H2}} = 2.41$ Hz, 1H, H1exo), 5.23 (d, $^3J_{\text{H1-H2}} = 2.41$ Hz, 0.33H, H1endo), 4.47 (dd, $^3J_{\text{H2-H1}} = 2.45$ Hz, $^3J_{\text{H2-H3}} = 4.14$ Hz, 1H, H2(exo)), 4.27 (dd, $^3J_{\text{H2-H1}} = 2.47$ Hz, $^3J_{\text{H2-H3}} = 4.39$ Hz, 0.33H, H2endo), 3.89–3.83 (two dd overlapping, 1.33H, H6(endo + exo)), 3.77 (dd, $^2J_{\text{H3-H4}} = 9.46$ Hz, $^3J_{\text{H3-H2}} = 4.3$ Hz, 0.33H, H3endo), 3.73–3.63 (m, 3H, H3(exo + endo), H6'exo, H4endo), 3.57 (t, $^3J_{\text{H4-H5}} = 9.5$ Hz, 1H, H4exo), 3.42 (s, 1H, $-\text{O}-\text{CH}_3$ (endo)), 3.28 (s overlapped with m, 3H, $-\text{O}-\text{CH}_3$ (exo), 0.3H, H5endo), 3.24 (m, 1H, H5exo), 1.63 (s, 3H, $-\text{CH}_3$ (exo)), 1.48 (s, 1H, $-\text{CH}_3$ (endo)). HR-MS: (not measured here).

2.3.5 1,2-*O*-(1-Methoxyethylidene)-3,4,6-tri-*O*-benzyl- D -mannopyranoside (6**).** This compound was synthesized as described by Ahadi *et al.*⁹ The crude product 1,2-*O*-(1-methoxyethylidene)- D -mannopyranoside (**5**) was dissolved in 300 mL of anhydrous dimethylformamide and cooled to 0 °C for 10 min. Subsequently, 7.75 g (323.05 mmol) sodium hydride was added over 10 min and the resulting suspension was stirred for 15 min. Next, 55.25 g (323.05 mmol, 38.39 mL) of benzyl bromide was added, and the solution was left to stir overnight. After checking for completion by TLC (3 : 1, *n*-hexane : ethyl acetate v/v, $R_f = 0.4$), the reaction was stopped by the addition of 80 mL methanol. The solution was extracted twice with 250 mL of ethyl acetate, and the collected organic phases were dried over magnesium sulphate. After removing the solvents under reduced pressure, the crude product was purified by column chromatography using an automated flash chromatography system with a running mixture of *n*-hexane and ethyl acetate (3 : 1, v/v). This method was also partially successful in separating the resulting endo : exo isomeric mixture. A running mixture of toluene and ethyl acetate (3 : 1, v/v) was also used as a substitute in a different trial, which provided a similar separation. The final yield was 73%. $^1\text{H-NMR}$: (600 MHz, chloroform- d) δ (ppm) 7.42–7.14 (m, overlapping with the singlet from CHCl_3 , 15H, Ar-H), 5.35 (d, $^3J_{\text{H1-H2}} = 2.58$ Hz, 1H, H1), 4.90 (d, $^3J_{\text{H9-H10/11}} = 10.70$ Hz, 1H, $-\text{O}-\text{CH}_2$), 4.82–4.75 (m, 2H, $-\text{O}-\text{CH}_2$), 4.63–4.58 (m, 2H, $-\text{O}-\text{CH}_2$), 4.55 (d, $^3J_{\text{H9-H10/11}} = 12.09$ Hz, 1H, $-\text{O}-\text{CH}_2$), 4.40 (dd, $^3J_{\text{H2-H3}} = 4.02$ Hz, $^3J_{\text{H2-H1}} = 2.56$ Hz, 1H, H2), 3.92 (t, $^3J_{\text{H4-H5}} = 9.31$ Hz, 1H, H4), 3.78–3.68 (m, 3H, H6, H6' H3), 3.45–3.40 (m, 1H, H5), 3.29 (s, 3H, $-\text{O}-\text{CH}_3$), 1.74 (s, 3H, $-\text{CH}_3$). HR-MS: calculated for $\text{C}_{30}\text{H}_{34}\text{NaO}_7$ $[\text{M} + \text{Na}]^+$ 529.2197; found 529.2198. RP-HPLC: (not measured here).

2.3.6 1-*O*-(2-Mercaptoethyl)-2-*O*-acetyl-3,4,6-tri-*O*-benzyl- D -mannopyranoside (7a**).** This compound was synthesized as described by Baressi *et al.*¹⁷ 1,2-*O*-(1-methoxyethylidene)-3,4,6-tri-*O*-benzyl- D -mannopyranoside (**6**) (1.5 g, 2.96 mmol) was added to 8.97 mL ethanethiol under inert gas and cooled to 0 °C for 15 minutes. Boron trifluoride diethyl etherate (1 eq., 2.96 mmol, 6.375 mL) was then added at 0 °C for 15 min before the reaction was stopped by adding 1.5 mL water and stirring for an additional 15 minutes. The ethanethiol was evaporated, leaving a clear oil. This was dissolved in 50 mL dichloromethane and washed three times each with 50 mL water. The organic phase was dried over magnesium sulphate and the solvent removed under reduced pressure by rotary evaporation. The crude product was then purified by column



chromatography with a running mixture of *n*-hexane:ethyl acetate (2 : 1, v/v) to provide the desired product **7** in 47% yield. ¹H-NMR: (600 MHz, chloroform-*d*) δ (ppm) 7.37–7.13 (m, overlapping with the singlet from CHCl₃, 15H, Ar-H), 5.43 (dd, ³*J*_{H2-H3} = 2.91 Hz, ³*J*_{H2-H1} = 1.64 Hz, 1H, H2), 5.32 (d, ³*J*_{H1-H2} = 1.62 Hz, 1H, H1), 4.85 (d, ³*J*_{H10-H11/12} = 10.7 Hz, 1H, –O–CH₂), 4.68 (dd, ³*J*_{H10-H11/12} = 11.6, 2.0 Hz, 2H, –O–CH₂), 4.56–4.46 (m, 3H, O–CH₂), 4.18–4.14 (m, 1H, H4), 3.96–3.89 (m, 2H, H6, H3), 3.84 (dd, ²*J*_{H6'-H6} = 10.82 Hz, ³*J*_{H6'-H5} = 4.29 Hz, 1H, H6'), 3.69 (dd, ³*J*_{H5-H6} = 10.83, ³*J*_{H5-H4} = 1.97 Hz, 1H, H5), 2.70–2.54 (m, 2H, –S–CH₂–CH₃), 2.16 (s, 3H, –C(O)–CH₃), 1.30–1.26 (m, 3H, –S–CH₂–CH₃). HR-MS: calculated for C₃₁H₄₀NO₆S [M + NH₄]⁺ 554.2571; found 554.2568. RP-HPLC: (linear gradient from 0 to 50 vol% MeCN in H₂O in 30 min at 25 °C) *t*_R = 16.74 min.

2.3.7 1-O-(2-Bromoethyl)-2-O-acetyl-3,4,6-tri-O-benzyl-D-mannopyranoside (7b-I). This compound was synthesized as described by Baressi *et al.*¹⁷ 1,2-O-(1-methoxyethylidene)-3,4,6-tri-O-benzyl-D-mannopyranoside (**6**) (2 g, 4 mmol) was dissolved in 40 mL dichloromethane under inert gas at 0 °C and stirred for 2 h. Subsequently, 2-bromoethanol (4.8 mmol, 0.34 mL) was added in one portion at 0 °C followed by the dropwise addition of boron trifluoride diethyl etherate (20 mmol, 2.53 mL). The ice bath was removed after complete addition, and the solution was left to stir overnight at room temperature. After checking for complete conversion by TLC (2 : 1, *n*-hexane : ethyl acetate, v/v, *R*_f = 0.5), the orange solution was washed three times each with ice water and then cold sodium hydrogen carbonate solution (30 mL per washing). The organic phase was dried over magnesium sulphate and the solvent was removed under reduced pressure on a rotary evaporator. The crude product in a yield of 91% was used in the next reaction without further purification. ¹H-NMR (600 MHz, chloroform-*d*) δ (ppm) 7.39–7.09 (m, overlapping with the singlet from CHCl₃, 15H, Ar-H), 5.39 (dd, ³*J*_{H2-H3} = 3.40 Hz, ³*J*_{H2-H1} = 1.85 Hz, 1H, H2), 4.90 (d, ³*J*_{H1-H2} = 1.87 Hz, 1H, H1), 4.86 (d, ³*J*_{H10-H11/12} = 10.73 Hz, 1H, –O–CH₂), 4.76–4.62 (m, 3H, –O–CH₂), 4.60–4.45 (m, 5H, –O–CH₂), 4.01–3.93 (m, 3H, H4, –O–CH₂–CH₂), 3.89–3.87 (m, 2H, H6, H3), 3.83–3.78 (m, 1H, H6'), 3.74–3.68 (m, 1H, H5), 3.50–3.44 (m, 2H, –O–CH₂–CH₂), 2.15 (s, 3H, –C(O)–CH₃). HR-MS: calculated for C₃₁H₃₉BrNO₇ [M + NH₄]⁺ 616.1904; found 616.1903. RP-HPLC: (linear gradient from 0 to 50 vol% MeCN in H₂O in 30 min at 25 °C) *t*_R = 28.90 min.

2.3.8 1-O-(2-Azidoethyl)-2-O-acetyl-3,4,6-tri-O-benzyl-D-mannopyranoside (7b-II). This compound was synthesized as described by Neralkar *et al.*¹⁸ 1-O-(2-bromoethyl)-2-O-acetyl-3,4,6-tri-O-benzyl-D-mannopyranoside (**7b-I**) (2.2 g, 3.67 mmol) was dissolved in 50 mL dimethylformamide. Sodium azide (5 eq., 18.35 mmol, 1.19 g) was then added to the solution and the resulting suspension was heated to 55 °C. Reaction progression was monitored by TLC (3 : 1, *n*-hexane : ethyl acetate, v/v, *R*_f = 0.4) and the reaction was diluted with 50 mL toluene after complete conversion in about 6 h. The solvents were removed under reduced pressure by rotary evaporation and dried at high vacuum. The resulting product **7b-II** was used without purification in the next step. ¹H-NMR (600 MHz, chloroform-*d*) δ (ppm) 7.37–7.09 (m, overlapping with the singlet from CHCl₃, 15H, Ar-H), 5.39 (dd, ³*J*_{H2-H3} = 3.40 Hz, ³*J*_{H2-H1} =

1.85 Hz, 1H, H2), 4.90 (d, ³*J*_{H1-H2} = 1.87 Hz, 1H, H1), 4.86 (d, ³*J*_{H10-H11/12} = 10.73 Hz, 1H, –O–CH₂), 4.72–4.65 (m, 3H, –O–CH₂), 4.56–4.45 (m, 4H, –O–CH₂), 4.03–3.99 (m, 1H, –O–CH₂–CH₃), 3.91–3.76 (m, 5H, H4, H6, H6', H3), 3.73–3.69 (m, 1H, H6'), 3.64–3.59 (m, 1H, –O–CH₂–CH₂), 3.41–3.35 (m, 2H, –O–CH₂–CH₂), 2.15 (s, 3H, –C(O)–CH₃). HR-MS: calculated for C₃₁H₃₉N₄O₇ [M + NH₄]⁺ 579.2813; found 579.2808. RP-HPLC: (linear gradient from 0 to 50 vol% MeCN in H₂O in 30 min at 25 °C) *t*_R = 28.34 min.

2.3.9 1-O-(2-Azidoethyl)-3,4,6-tri-O-benzyl-D-mannopyranoside (8). This compound was synthesized as described by Neralkar *et al.*¹⁸ 1-O-(2-azidoethyl)-2-O-acetyl-3,4,6-tri-O-benzyl-D-mannopyranoside (**7b-II**) was dissolved in 61.5 mL methanol and then 10 mL of a 1 M sodium methoxide solution was added dropwise. The solution was stirred for 2 h, while monitoring reaction progress by TLC (2 : 1, *n*-hexane : ethyl acetate, v/v, *R*_f = 0.3). Upon completion, the solvent was removed under reduced pressure by rotary evaporation. For purification, the crude product was separated by column chromatography with a running mixture of *n*-hexane:ethyl acetate (3 : 1, v/v) to provide the desired product **8** in 42% yield. ¹H-NMR (600 MHz, chloroform-*d*) δ (ppm) 7.39–7.14 (m, overlapping with the singlet from CHCl₃, 15H, Ar-H), 4.95 (d, ³*J*_{H1-H2} = 1.69 Hz, 1H, H1), 4.82 (d, ³*J*_{H10-H11/12} = 10.8 Hz, 1H, –O–CH₂), 4.71–4.67 (m, 2H, –O–CH₂), 4.64 (d, ³*J*_{H10-H11/12} = 12.2 Hz, 1H, –O–CH₂), 4.55–4.49 (m, 2H, –O–CH₂), 4.07 (dd, ³*J*_{H2-H3} = 3.33 Hz, ³*J*_{H2-H1} = 1.74 Hz, 1H, H2), 3.93–3.87 (m, 2H, H3, H4), 3.86–3.82 (m, 1H, H5), 3.82–3.78 (m, 1H, –O–CH₂–CH₂), 3.76–3.68 (m, 2H, H6, H6'), 3.65–3.60 (m, 1H, –O–CH₂–CH₂), 3.43–3.32 (m, 2H, –O–CH₂–CH₂). HR-MS: calculated for C₂₉H₃₇N₄O₆ [M + NH₄]⁺ 537.2708; found 537.2704. RP-HPLC: (linear gradient from 0 to 50 vol% MeCN in H₂O in 30 min at 25 °C) *t*_R = 14.76.

2.3.10 1'-O-(2-Ethylazid)-2-O-acetyl-hexa-O- α -1,2-benzyl-mannobiose (9). This protocol was inspired by work by Pathak *et al.*¹¹ 1-O-(2-Azidoethyl)-3,4,6-tri-O-benzyl-D-mannopyranoside (**8**) (660 mg, 1.27 mmol) was dissolved in 20 mL dry dichloromethane over 4 Å molecular sieve and cooled to –18 °C using a saline/ice bath. To the solution was added 1-O-(2-mercaptoethyl)-2-O-acetyl-3,4,6-tri-O-benzyl-D-mannopyranoside (**7a**) (600 mg, 1.12 mmol) which was predissolved in 10 mL dry dichloromethane. After about 20 min, 510 mg *N*-iodosuccinimide (2 eq., 2.25 mmol) and 230 mg tin trifluoromethanesulfonate (0.5 eq., 0.56 mmol) were added, resulting in a red coloured solution. The cooling bath was then removed and the solution allowed to stir at room temperature for 30 min before stopping by the addition 1 mL of triethylamine. The quenched reaction solution was filtered over Celite and diluted with 100 mL dry dichloromethane. The organic phase was washed with a sodium thiosulphate solution, forming an emulsion in addition to phase separation. The emulsion phase was washed again with dichloromethane to extract the product. The collected organic phases were dried over magnesium sulphate and concentrated by rotary evaporation under reduced pressure. The brown crude product was purified by column chromatography using a running mixture of *n*-hexane : ethyl acetate (3 : 1, v/v) to provide the desired product **9** in 58% yield and 91% relative purity (determined by HPLC). ¹H-NMR

(600 MHz, chloroform-*d*) δ (ppm) 7.36–7.15 (m, overlapping with the singlet from CHCl₃, 30H, Ar-H), 5.53 (dd, $^3J_{H2-H3} = 3.33$ Hz, $^3J_{H2-H1} = 1.86$ Hz, 1H, H2), 5.03 (d, $^3J_{H1-H2} = 1.81$ Hz, 1H, H1), 4.94 (d, $^3J_{H1'-H2'} = 1.92$ Hz, 1H, H1'), 4.87–4.83 (m, 2H, –O–CH₂), 4.70–4.62 (m, 5H, –O–CH₂), 4.54 (t, $^3J_{H10-H11/12} = 11.02$ Hz, 2H, –O–CH₂), 4.48 (t, $^3J_{H10-H11/12} = 11.23$ Hz, 2H, –O–CH₂), 4.41 (d, $^3J_{H10-H11/12} = 10.93$ Hz, 1H, –O–CH₂), 4.01–3.91 (m, 4H), 3.84–3.68 (m, 7H), 3.41–3.35 (m, 1H, –O–CH₂–CH₃), 3.30–3.18 (m, 2H, –O–CH₂–CH₃), 2.13 (s, 3H, –C(O)–CH₃). An exact assignment of the carbohydrate signals of both mannose units in the range of 4.01 to 3.68 ppm has not been made due to the very similar chemical environment. ¹³C-NMR (100 MHz, chloroform-*d*) δ (ppm) 170.22, 138.47, 138.44, 138.42, 138.37, 138.23, 138.04, 128.83–127.34 (m), 99.78, 98.86, 79.54, 78.14, 75.17, 75.10, 74.50, 74.47, 73.53, 73.36, 72.23, 72.14, 71.97, 71.90, 69.36, 69.29, 68.97, 68.78, 66.53, 50.46, 21.20. HR-MS: calculated for C₅₈H₆₇N₄O₁₂ [M + NH₄]⁺ 1011.4750; found 1011.4743. RP-HPLC: (linear gradient from 0 to 50 vol% MeCN in H₂O in 30 min at 25 °C) *t*_R = 15.77 min, relative purity 91%

2.4 Solid phase glycomacromolecule synthesis

The oligo(amidoamine) scaffold was built up step by step using the general coupling and deprotection protocol with building blocks EDS and TT, which were synthesized according to literature.^{19,20} The preparation size/scale of the oligo(amidoamine) scaffold was 0.2 mmol. The resin used was a TentaGel® S RAM resin preloaded with ethylenediamine. Before each reaction on the resin, the resin was allowed to swell in DCM for approx. 20 min and subsequently washed five times with the solvent of the following reaction.

2.4.1 General coupling protocol. The Fmoc protecting group was deprotected using 25 vol% piperidine in dimethylformamide twice for 15 min each time. Between the deprotections the resin was washed five times with dimethylformamide. After deprotection, the resin was washed twenty times with dimethylformamide before five equivalents of the building block (1 mmol, 470 mg EDS or 335 mg TT), together with five equivalents of PyBOP (1 mmol, 520 mg) as coupling reagent and ten equivalents of *N,N*-diisopropylethylamine (2 mmol, 0.34 mL) were dissolved in 3 mL dimethylformamide and added to the resin for coupling. After one hour, the resin was washed again ten times with dimethylformamide.

2.4.2 Coupling of the carbohydrate ligands. For the attachment of the carbohydrate functionalities to the backbones of the oligomers, 2.5 eq. of the carbohydrate azide were used for each alkyne group (0.2 mmol batch was split in half so 7.5 eq., 0.75 mmol, 746 mg). These were dissolved in 2 mL dimethylformamide. In addition, 10 mg copper sulphate per alkyne functionality and 10 mg sodium ascorbate per alkyne functionality were each dissolved in 0.5 mL MQ water. The solutions were drawn up one after the other. The reaction took place under exclusion of light overnight. For purification, after the reaction, the resin was washed ten times with a 23 mM solution of sodium diethyldithiocarbamate in dimethylformamide/water (1 : 1, v/v), ten times with dimethylformamide and ten times with dichloromethane. These steps were repeated

until no discoloration of the sodium diethyldithiocarbamate was visible.

2.4.3 Recovery of the α -1,2-mannobioseazide after the CuAAC. The reaction solution of the CuAAC was collected and diluted with 40 mL additional water. The aqueous phase was then extracted three times with 20 mL ethyl acetate each time and the organic phases were collected. After drying the organic phase with magnesium sulphate, the ethyl acetate was removed by rotary evaporation to yield an oily residue. This was mixed with about 20 mL chloroform to remove insoluble impurities. Finally, an attempt was made to remove the dimethylformamide residue by coevaporation with toluene or drying in high vacuum. However, according to ¹H-NMR analysis, dimethylformamide residues remained in the raw product. These should be purified by column chromatography before being used again (see appendix).

2.4.4 Deprotection of the acetyl protecting groups on the solid phase. To deprotect the acetyl groups of the carbohydrate ligand, the resin was first washed three times with methanol and then shaken for one hour with a 0.1 M solution of sodium methanolate in methanol. Subsequently, the resin was washed ten times each with methanol, dimethylformamide and dichloromethane.

2.4.5 Cleavage of the glycomacromolecules from the solid phase. A cleavage solution consisting of 60 vol% trifluoroacetic acid, 35 vol% dichloromethane and 5 vol% triisopropylsilane was used to cleave the glycomacromolecules from the solid phase. The solution was drawn up into the syringe and shaken for 20 min. The solution was then precipitated in cold diethyl ether. For each cleavage, these steps were repeated three times for complete detachment of the glycomacromolecules from the resin. After centrifugation of the diethyl ether mixture, the glycomacromolecules were dried by lyophilization.

2.4.6 Deprotection of the benzyl protecting groups in solution. For the deprotection of the benzyl groups in solution, the benzyl protected glycomacromolecule **F2** was dissolved in approx. 30 mL methanol (after cleavage from the solid phase) and rapidly stirred with palladium on activated carbon under a hydrogen atmosphere for 24 h. After filtering off the palladium catalyst, only partial deprotection was detected by analysis of the MALDI TOF MS and ¹H-NMR spectra. For this reason, the deprotection was carried out again for 72 h resulting in complete deprotection. After complete deprotection and purification *via* HPLC, 2.5 mg of final product **F2** were obtained. ¹H-NMR (600 MHz, D₂O) δ (ppm) 8.46 (s, 2H, –NH₂), 7.70 (d, *J* = 8.2 Hz, 1.5H, *j*), 7.39 (d, *J* = 8.2 Hz, 1.5H, *j*) 4.29 (s, 3H, *i*), 4.11–3.99 (m, 3H, *h*), 3.84–3.74 (m, 24H, *k*, *l*, *g*), 3.44–3.25 (m, 54H, *e*, *f*, *h*, *i*, 24xBiMan), 2.60 (t, *J* = 7.0 Hz, 4H, *a*, *b*), 2.47–2.39 (m, 6H, BiMan), 2.16–2.01 (m, 49H, *c*, *d*, 12xBiMan, CH₃CH solvent impurity).

3 Results and discussion

3.1 α -1,2-Mannobioseazide synthesis

Our synthetic approach, inspired by Groneborn *et al.*, is shown in Fig. 1.¹² The key requirement of the approach is the generation of a regio- and stereoselective α -1,2-connection between the two






Fig. 1 Synthetic pathway of final α -1,2-mannobiose disaccharide **9** starting from D-(+)-mannose.

mannose units to obtain desired product **9** with both a linker in place for conjugation, and a temporary protecting group in the 2'-O-position for possible extension. For this purpose, we envisioned generating two different glycosides from known orthoester **6** (ref. 9): (i) known glycosyl donor **8** (ref. 18) bearing a shelf stable thioglycoside which could be readily activated for glycosylation, and (ii) glycosyl acceptor **7a** (ref. 17) bearing an azido linker for further conjugation *e.g.*, for presentation on a multivalent scaffold. To ensure the regio- and stereoselective formation of the desired α -1,2-linkage, an orthogonal protecting group strategy was employed, and a 2-O-acetate protecting group was initially installed to drive α -selectivity during glycosylation. This group could then be selectively deprotected for subsequent glycosylation. Meanwhile, the installation of O-benzyl groups more distant from the anomeric site could serve to arm each monosaccharide for glycosylation.²¹ Notably, orthoester **6** can be prepared in high yields from readily available D-mannose over four steps.⁹ Overall, the resulting split and combine approach consisted of ten steps from commercially available D-mannose to the desired novel α -1,2-mannobioside **9**.

The synthesis of compound **9** is shown in Fig. 2. Known orthoester **6** was prepared based on work by Ahadi *et al.*⁹ Acetylation of α -D-mannose **1** under acidic conditions gave **2** in near quantitative yield. Bromination of **2** with hydrogen bromide in acetic acid gave **3** almost exclusively as the α -anomer in 97% yield, with the stereochemistry of this reaction being driven by the neighboring group effect of the acetylated 2-O-position which creates an intermediate oxonium ion that blocks the top face of the sugar. In the next step, the C2-acetyl group, aided by the assistance of 2,4,6-trimethylpyridine, underwent an intramolecular substitution reaction at the anomeric position. The resulting acetone was then captured by methanol to generate orthoester **4** in 57% yield after purification. The acetyl protecting groups of **4** were hydrolyzed with sodium methoxide in methanol to yield **5**, which was subsequently benzylated with benzyl chloride in sodium hydroxide to afford **6** in a yield of 73% over two steps and after purification *via* chromatography. This key intermediate was then split and used in the second part of the synthesis.

The second part of the synthesis required the introduction of the azide linker to **6** to generate known compound **8** for multivalent presentation, and the addition of the thiol group to **6** to generate **7a** for subsequent glycosylation with **8**; both reactions required nucleophilic ring opening of the orthoester. The synthesis of compound **8** was based on work by Neralkar *et al.*¹⁸ Anomeric substitution of **6** with 2-bromoethanol *via* Lewis acid catalyzed activation, followed by nucleophilic substitution at the resulting primary bromide with sodium azide afforded crude compound **7b** in 91% yield over two steps. Subsequent deprotection of the temporary acetyl protecting group at the C2 position of **7b** *via* sodium methanolate yielded glycosyl acceptor **8** as a single anomer in 42% after purification. The synthesis of glycosyl donor **7a** was based on work by Barresi *et al.*¹⁷ Orthoester **6** was activated under Lewis acid catalyzed conditions, but this time in the presence of ethanethiol. This provided a 47% yield of the desired product **7a** after purification *via* chromatography.

With both donor **7a** and acceptor **8** in hand, the next step involved a stereoselective glycosylation reaction to generate the novel compound **9**. To achieve this, *N*-iodosuccinimide and tin(II) trifluoromethanesulfonate were added to a mixture containing **7a** and **8** under argon atmosphere at -20°C . The reaction was monitored by TLC until completion. The desired α -1,2-mannobioseazide product **9** was achieved in 58% yield after column chromatography. The final, overall yield of the ten step sequence required to produce α -1,2-mannobioseazide was 8.77%.

3.2 Multivalent α -1,2-mannobiose glycomacromolecule synthesis

After successful synthesis and isolation of the α -1,2-mannobioseazide ligand, a trivalent precision glycomacromolecule based on an oligo(amidoamine) scaffold **F2** was constructed using solid-phase synthesis as shown in Fig. 3. This structure was inspired by previous efforts in our group to target C-type lectins with precision glycomacromolecules designed to mimic high-mannose/mannose rich glycans.^{22,23} In this work, we chose to focus on a unique and novel ligand consisting of





Fig. 2 Synthesis of α -1,2-mannobioseazide starting from D-(+)-mannose **1** via orthoester **6**. (a) Ac_2O , MeCN, 24 h. (b) HBr, AcOH, 16 h. (c) 2,4,6-trimethylpyridine, MeOH, 16 h. (d) NaOMe, DCM, MeOH, 2 h. (e) BnBr, NaH, DMF, 16 h. (f) EtSH, $BF_3 \cdot OEt_2$, 30 min. (g) BrEtOH, $BF_3 \cdot OEt_2$, DCM, 16 h. (h) NaN_3 , DMF, 55 °C. (i) NaOMe, DCM, MeOH, 2 h. (j) NIS, $Sn(OTf)_2$, DCM, -20 °C, 30 min.

a hydrophilic tail group conjugated to a functionalizable trivalent head group for optimal presentation of the α -1,2-mannobiose ligand. The EDS (ethylene glycol diamine succinic acid) building block was selected as a spacer unit to enhance the flexibility and hydrophilicity of the ligand. Notably the choice of resin ensured a terminal amine at the end of the EDS spacer which is of special interest to our work as we endeavor to

present these ligands on surfaces and membranes for further investigation. The use of the TT (trivalent triple bond) building block was selected for presentation of the α -1,2-mannobiose ligand, and was chosen for its ability to mimic the way high mannose oligosaccharides are presented to C-type lectins found in nature, *e.g.* $Man_9GlcNAc_2$.^{24,25} Furthermore, the close distance between the alkyne groups in the TT building block





Here we adopt an efficient, split and mix approach for the synthesis of a novel α -1,2-mannobiose analog bearing an azide linker for conjugation (**9**) from known precursors. The synthetic route described here has several advantages. First, compound **9** can be synthesized from an easily accessible and inexpensive orthoester precursor (**6**) which can be prepared on gram scales. Second, the glycosylation conditions provide for the installation of a wide variety of possible linkers. Finally, the temporary 2-*O*-acetyl protecting that is generated on nucleophilic ring opening of **6** provides the possibility of selectively elongating/functionalizing the disaccharide with a wide range of

substrates, which in turn allows for the possibility of further customization and adaptivity.

The multivalent presentation of α -1,2-mannobiose on a precision glycomacromolecule (F2) was also achieved using a solid support approach. Notably, the disadvantage of having to use higher equivalents of building blocks during solid-supported synthesis steps and glycoconjugation *via* CuAAC was mitigated by their collection, recycling, and reuse, making the overall process highly efficient. Furthermore, the terminal amine group and long flexible linker consisting of the EDS units make the compound well suited for presentation on surfaces to better mimic the native presentation of these types of structures.

The final precision glycomacromolecule presenting the α -1,2-mannobiose in a trivalent fashion represents an interesting example for the investigation into the affinity of C-type lectins towards the multivalent presentation of α -1,2-mannobiose ligands. We believe its presentation is likely to mimic high-mannose containing natural glycans that are known to engage C-type lectins like langerin and DC-SIGN. Indeed, our current efforts involve expanding the methodology reported here to generate a library of similar structures like the one presented here to evaluate their binding towards langerin and DC-SIGN to examine possible trends for selectivity and affinity.

Data availability

The data supporting this article has been included as part of the ESI.†

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

NLS would like to thank Davidson College for a Faculty Study and Research Grant, and the National Science Foundation for partial support through an International Research Experience for Scientists grant (#1854028). We would also like to thank the analytical facilities at Heinrich-Heine-Universität, Duesseldorf for support with ^1H -NMR and MS analysis.

References

- 1 H. Feinberg, S. A. F. Jégouzo, M. J. Rex, K. Drickamer, W. I. Weis and M. E. Taylor, Mechanism of pathogen recognition by human dectin-2, *J. Biol. Chem.*, 2017, **292**, 13402–13414.
- 2 Y. Guo, H. Feinberg, E. Conroy, D. A. Mitchell, R. Alvarez, O. Blixt, M. E. Taylor, W. I. Weis and K. Drickamer, Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR, *Nat. Struct. Mol. Biol.*, 2004, **11**, 591–598.
- 3 J. M. Irache, H. H. Salman, C. Gamazo and S. Espuelas, Mannose-targeted systems for the delivery of therapeutics, *Expert Opin. Drug Delivery*, 2008, **5**, 703–724.
- 4 A. M. Kerrigan and G. D. Brown, C-type lectins and phagocytosis, *Immunobiology*, 2009, **214**, 562–575.
- 5 V. Porkolab, E. Chabrol, N. Varga, S. Ordanini, I. Sutkevičiūtė, M. Thépaut, M. J. García-Jiménez, E. Girard, P. M. Nieto, A. Bernardi and F. Fieschi, Rational-Differential Design of Highly Specific Glycomimetic Ligands: Targeting DC-SIGN and Excluding Langerin Recognition, *ACS Chem. Biol.*, 2018, **13**, 600–608.
- 6 P. Valverde, J. D. Martínez, F. J. Cañada, A. Ardá and J. Jiménez-Barbero, Molecular Recognition in C-Type Lectins: The Cases of DC-SIGN, Langerin, MGL, and L-Sectin, *ChemBioChem*, 2020, **21**, 2999–3025.
- 7 E.-C. Wamhoff, J. Schulze, L. Bellmann, M. Rentzsch, G. Bachem, F. F. Fuchsberger, J. Rademacher, M. Hermann, B. Del Frari, R. van Dalen, D. Hartmann, N. M. van Sorge, O. Seitz, P. Stoitzner and C. Rademacher, A Specific, Glycomimetic Langerin Ligand for Human Langerhans Cell Targeting, *ACS Cent. Sci.*, 2019, **5**, 808–820.
- 8 M. K. Patel, B. Vijayakrishnan, J. R. Koeppe, J. M. Chalker, K. J. Doores and B. G. Davis, Analysis of the dispersity in carbohydrate loading of synthetic glycoproteins using MALDI-TOF mass spectrometry, *Chem. Commun.*, 2010, **46**, 9119–9121.
- 9 S. Ahadi, S. I. Awan and D. B. Werz, Total Synthesis of Tri-, Hexa- and Heptasaccharidic Substructures of the O-Polysaccharide of *Providencia rustigianii* O34, *Chem.-Eur. J.*, 2020, **26**, 6264–6270.
- 10 S. Boonyarattanakalin, X. Liu, M. Michieletti, B. Lepenies and P. H. Seeberger, Chemical Synthesis of All Phosphatidylinositol Mannoside (PIM) Glycans from *Mycobacterium tuberculosis*, *J. Am. Chem. Soc.*, 2008, **130**, 16791–16799.
- 11 A. K. Pathak, V. Pathak, J. M. Riordan, S. S. Gurcha, G. S. Besra and R. C. Reynolds, Synthesis of mannopyranose disaccharides as photoaffinity probes for mannosyltransferases in *Mycobacterium tuberculosis*, *Carbohydr. Res.*, 2004, **339**, 683–691.
- 12 G. Nestor, T. Anderson, S. Oscarson and A. M. Gronenborn, Exploiting Uniformly ^{13}C -Labeled Carbohydrates for Probing Carbohydrate-Protein Interactions by NMR Spectroscopy, *J. Am. Chem. Soc.*, 2017, **139**, 6210–6216.
- 13 S. A. Hill, C. Gerke and L. Hartmann, Recent Developments in Solid-Phase Strategies towards Synthetic, Sequence-Defined Macromolecules, *Chem.-Asian J.*, 2018, **13**, 3611–3622.
- 14 S. Boden, F. Reise, J. Kania, T. K. Lindhorst and L. Hartmann, Sequence-Defined Introduction of Hydrophobic Motifs and Effects in Lectin Binding of Precision Glycomacromolecules, *Macromol. Biosci.*, 2019, **19**, 1800425.
- 15 D. Ponader, P. Maffre, J. Aretz, D. Pussak, N. M. Ninnemann, S. Schmidt, P. H. Seeberger, C. Rademacher, G. U. Nienhaus and L. Hartmann, Carbohydrate-Lectin Recognition of Sequence-Defined Heteromultivalent Glycooligomers, *J. Am. Chem. Soc.*, 2014, **136**, 2008–2016.
- 16 T. Freichel, D. Laaf, M. Hoffmann, P. B. Konietzny, V. Heine, R. Wawrzinek, C. Rademacher, N. L. Snyder, L. Elling and



- L. Hartmann, Effects of linker and liposome anchoring on lactose-functionalized glycomacromolecules as multivalent ligands for binding galectin-3, *RSC Adv.*, 2019, **9**, 23484–23497.
- 17 F. Barresi and O. Hindsgaul, The synthesis of β -mannopyranosides by intramolecular aglycon delivery: scope and limitations of the existing methodology, *Can. J. Chem.*, 1994, **72**, 1447–1465.
 - 18 M. Neralkar, L. Tian, R. L. Redman and I. J. Krauss, Synthesis of Mannosidase-Stable Man3 and Man4 Glycans Containing S-linked Man α 1 \rightarrow 2Man Termini, *Org. Lett.*, 2021, **23**, 3053–3057.
 - 19 D. Ponader, F. Wojcik, F. Beceren-Braun, J. Dervede and L. Hartmann, Sequence-Defined Glycopolymer Segments Presenting Mannose: Synthesis and Lectin Binding Affinity, *Biomacromolecules*, 2012, **13**, 1845–1852.
 - 20 S. Üclü, C. Marschelke, F. Drees, M. Giesler, D. Wilms, T. Köhler, S. Schmidt, A. Synytska and L. Hartmann, Sweet Janus Particles: Multifunctional Inhibitors of Carbohydrate-Based Bacterial Adhesion, *Biomacromolecules*, 2024, **25**, 2399–2407.
 - 21 D. R. Mootoo, P. Konradsson, U. Udodong and B. Fraser-Reid, Armed and disarmed n-pentenyl glycosides in saccharide couplings leading to oligosaccharides, *J. Am. Chem. Soc.*, 1988, **110**, 5583–5584.
 - 22 J. Valladeau, V. Duvert-Frances, J.-J. Pin, C. Dezutter-Dambuyant, C. Vincent, C. Massacrier, J. Vincent, K. Yoneda, J. Banchereau, C. Caux, J. Davoust and S. Saeland, The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface, *Eur. J. Immunol.*, 1999, **29**, 2695–2704.
 - 23 H. Feinberg, M. E. Taylor, N. Razi, R. McBride, Y. A. Knirel, S. A. Graham, K. Drickamer and W. I. Weis, Structural Basis for Langerin Recognition of Diverse Pathogen and Mammalian Glycans through a Single Binding Site, *J. Mol. Biol.*, 2011, **405**, 1027–1039.
 - 24 D. A. Mitchell, A. J. Fadden and K. Drickamer, A Novel Mechanism of Carbohydrate Recognition by the C-type Lectins DC-SIGN and DC-SIGNR: Subunit Organization and Binding to Multivalent Ligands, *J. Biol. Chem.*, 2001, **276**, 28939–28945.
 - 25 N. S. Stambach and M. E. Taylor, Characterization of carbohydrate recognition by langerin, a C-type lectin of Langerhans cells, *Glycobiology*, 2003, **13**, 401–410.
 - 26 F. Shamout, L. Fischer, N. L. Snyder and L. Hartmann, Recovery, Purification, and Reusability of Building Blocks for Solid Phase Synthesis, *Macromol. Rapid Commun.*, 2020, **41**, 1900473.

